| Name | Title | Contact Details |
|---|
Antheia is a science and technology company developing next generation plant-inspired medicines.
GKN Powder Metallurgy is the global leader in powder metal solutions, shaping the future with sustainable metal technologies that drive innovation and performance in the automotive and other industries. With a global manufacturing network comprised of 28 manufacturing facilities and 2 innovation centers across 9 countries, we produce 10 million high precision powder metal components daily and 250,000 tons of atomized metal powder per year. Our portfolio of advanced process technologies includes conventional PM for cost-effective, high-volume production; MIM (Metal Injection Molding) for complex, lightweight parts; powder forging for enhanced durability; aluminum PM for lightweight components; and metal additive manufacturing for innovative designs and scalable production. We provide solutions that enable electrification, including manufacturing custom parts for e-motors, e-drivetrains, magnets, batteries, drive-by-wire, and thermal management systems. Our collaborative approach allows us to develop tailor-made solutions that perfectly match your application and deliver superior performance, efficiency, and reduced weight. Sustainability is at the core of who we are. All our metal powders are made from 100% recyclable scrap metal and are designed with the circular economy in mind. Our dedication to combating climate change, minimizing waste, and upholding the highest social responsibility standards has earned us the EcoVadis Platinum medal - an award for excellence in ESG performance given only to the top 1% of companies globally. At GKN Powder Metallurgy, we are not just about manufacturing; we are about technology that impacts the world. Join us as we continue to lead, innovate, and shape the future of manufacturing.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.